Q: What solutions does OncoAtlas bring to patients and health professionals?
A: OncoAtlas is a science-based company that focuses on precision oncology. We develop and manufacture solutions that make genetic analysis accessible to cancer patients. Our products are designed to analyze solid tumors, including breast, colorectal, prostate, ovarian, pancreatic cancers, and melanoma. They allow patients and physicians to understand the molecular characteristics of tumors, guiding effective treatment selection and identifying potential resistance to therapies. We also provide solutions for assessing cancer risk in healthy individuals, offering preventive insights.
Our products target all solid tumors, excluding hematological cancers. We are developing additional products to cover less common tumor types, ensuring comprehensive diagnostic coverage. Our approach allows us to tailor solutions to the molecular characteristics of each cancer, improving precision and effectiveness.
Q: What opportunities do you see in Mexico, and how prepared is the country for your solutions?
A: The Mexican market is new to us, but we see a clear need for accessible, high-quality diagnostics. Like other countries, Mexico faces challenges in ensuring timely and effective cancer treatment. Our technology can address these needs by reducing analysis time and supporting more precise, personalized therapies. The demand for such solutions is present, and we see a strong opportunity to improve outcomes.
We aim to understand the Mexican market, including local regulatory requirements and market dynamics, to develop an effective strategy. We aim to identify partnership opportunities and provide solutions that meet local needs. Establishing connections with local companies and exploring collaborative models is central to our approach.
Q: How do you differentiate OncoAtlas from other genetic and personalized medicine companies entering the market?
A: Our products use targeted gene panels rather than broad, comprehensive panels, enabling cost-effective, precise analysis focused on genes strongly associated with specific cancers. We also provide proprietary software that converts raw sequencing data into actionable reports for patients and physicians. The software is flexible, allowing qualified users to make adjustments while enabling labs with limited resources to operate without additional specialists. Our strong R&D capabilities, in-house investigations, and collaborations with leading federal hospitals in Russia further strengthen our scientific and clinical credibility.
Q: What potential partnerships is OncoAtlas exploring in Mexico?
A: We have identified Theranomics, a Mexican company that partners with insurance providers to optimize cancer treatment plans. It analyzes tumor samples to determine the most effective chemotherapy, reducing costs and improving outcomes. Our technology could complement its model by offering more affordable and efficient sequencing solutions, providing a strong foundation for collaboration and market entry. Theranomics has partnerships with two insurers, indicating significant potential for expansion through collaboration.
OncoAtlas is a precision oncology company that develops targeted genetic diagnostics for solid tumors. Its solutions guide personalized cancer treatment and assess cancer risk in healthy individuals.